Condition: Chronic Inflammatory Demyelinating Polyneuropathy · Myasthenia Gravis · Multiple Sclerosis · Sponsor: Kite, A Gilead Company
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.
This description comes directly from the study's public registry record.
Medical Information · 844-454-5483(1-844-454-KITE) · medinfo@kitepharma.com
Always discuss trial participation with your own doctor first.
| Stanford Neuroscience Health Center | Palo Alto, California, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| LDS Hospital - Intermountain Health | Salt Lake City, Utah, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
| Concord Repatriation General Hospital | Sydney, New South Wales, Australia | Recruiting |
| Corner Hawkesbury Road and Darcy Road | Westmead, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07304154